A carregar...
Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
Hodgkin’s lymphoma (HL) is usually sensitive and curative to multi-agent chemotherapy, but may become refractory disease in a subset of relapsed patients. Recent novel agents, brentuximab-vedotin (BV) and immune checkpoint inhibitors have significantly improve the treatment outcome. We report the ou...
Na minha lista:
| Publicado no: | J Hematol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elmer Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7188374/ https://ncbi.nlm.nih.gov/pubmed/32362983 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jh596 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|